What to Expect:
What to Expect:
Join LabCentral for our Genomics at Work: Innovation Showcase as we convene researchers, startups, and industry experts for an evening dedicated to the evolving world of genomics. Designed to spotlight the tools, technologies, and collaborations driving innovation in the field, the event features a dynamic mix of sponsor exhibits, interactive discussions, and a brief keynote followed by a fireside chat. Whether you’re exploring new workflows, seeking technical insight, or looking to connect with leaders in the genomics world, this showcase offers a unique opportunity to translate discovery and innovation into impact.
Join LabCentral for our Genomics at Work: Innovation Showcase as we convene researchers, startups, and industry experts for an evening dedicated to the evolving world of genomics. Designed to spotlight the tools, technologies, and collaborations driving innovation in the field, the event features a dynamic mix of sponsor exhibits, interactive discussions, and a brief keynote followed by a fireside chat. Whether you’re exploring new workflows, seeking technical insight, or looking to connect with leaders the NGS world, this showcase offers a unique opportunity to translate discovery and innovation into impact.
Agenda:
Registration & Networking
3:00 PM - 3:30 PM
Opening Remarks
3:30 PM - 3:35 PM
Keynote Speaker
3:35 PM - 3:45 PM
Fireside Chat
3:45 PM - 4:00 PM
Genomics Workflow Showcase & Networking
4:00 PM - 6:00 PM
Event Close
6:00 PM
Registration & Networking
3:00 PM - 3:30 PM
Opening Remarks
3:30 PM - 3:35 PM
Keynote Speaker
3:35 PM - 3:45 PM
Fireside Chat
3:45 PM - 4:00 PM
Genomics Workflow Showcase & Networking
4:00 PM - 6:00 PM
Event Close
6:00 PM
Agenda:
3:00 PM
3:30 PM
3:35 PM
3:45 PM
4:00 PM
6:00 PM
Registration & Networking
Opening Remarks
Keynote Speaker
Fireside Chat
Genomics Workflow Showcase & Networking
Event Close
Keynote Discussion
From Genomes to Generative Models: The New Era of Life Science Innovation
Niall Lennon, Ph.D.
Chief Scientific Officer & Board Chair
Broad Clinical Labs
Niall Lennon is the senior director of the genomics platform at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is also the chief scientific officer and chair of the board of Broad Clinical Laboratories, a wholly owned subsidiary of the institute, and an associate director of the Gerstner Center for Cancer Diagnostics. He oversees the development, implementation, validation, and operation of disruptive technologies and analytical methods to serve research, clinical research, and clinical diagnostics across a range of fields from infectious disease and cancer to rare and chronic diseases.
Lennon has been with the Broad since 2005, and has contributed to the development of applications for every major genomics technology. He also built a CLIA/CAP licensed clinical laboratory at the Broad (now known as Broad Clinical Labs) to facilitate return of results to patients and to support clinical trials. More recently, Lennon has led efforts to achieve FDA approval for both large-scale genomics projects (NIH’s All of Us Research Program) and for Broad’s own clinical diagnostic for COVID-19 testing process that delivered more than 37M diagnostic test results to people in the New England region.
Fireside Chat:
Morgan Maeder
Head of Research
Aurora Therapeutics
Morgan Maeder is currently the Head of Research at Aurora Therapeutics. She earned her Ph.D. in Genetics from Harvard University in the lab of J. Keith Joung where her work spanned multiple platforms, from zinc fingers and TALEs to CRISPR-Cas9, and from nuclease-based gene editing to epigenetic-based gene regulation. As the first scientist at Editas Medicine, she led the preclinical development of EDIT-101, a CRISPR-Cas9-based gene editing approach to treat Leber Congenital Amaurosis type 10. Following Editas, she spent 1.5 years as a consultant to Third Rock Ventures, helping to launch Faze Medicines, a company pioneering therapeutics based on biomolecular condensates. Most recently, she was the second employee at Chroma Medicine, where she served as Head of Platform Technologies, working to develop programmable epigenetic editors to specifically modulate gene expression as a novel approach to genetic medicine.
Christalyn Rhodes, Ph.D.
AVP, Genetic Medicine - External Partnerships & Academic Collaborations
Eli Lilly
Keynote Discussion:
From Genomes to Generative Models: The New Era of Life Science Innovation
Christalyn Rhodes is a biotech influencer and strategist who operates at the intersection of science and business to transform how medicines are discovered, developed, and delivered. As Lilly’s Associate Vice President of External Partnerships for Genetic Medicines, she scouted pivotal breakthrough technologies and built the infrastructure to accelerate their development. When gaps exist, she steps in as an inventor and interdisciplinary scientist, creating nuanced solutions and new platforms. Previously an investor and biotech entrepreneur, she identified high-impact opportunities and founded companies focused on diseases with substantial economic burden—designing technologies and authoring four pivotal patents that reversed the trajectory of a failing company and delivered more than $50 million in savings. She is committed to catalyzing life-saving therapies through collaborative efforts across academia and industry.
Niall Lennon, Ph.D.
Chief Scientific Officer & Board Chair
Broad Clinical Labs
Niall Lennon, Ph.D.
Chief Scientific Officer & Board Chair
Broad Clinical Labs
Niall Lennon is the senior director of the genomics platform at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is also the chief scientific officer and chair of the board of Broad Clinical Laboratories, a wholly owned subsidiary of the institute, and an associate director of the Gerstner Center for Cancer Diagnostics. He oversees the development, implementation, validation, and operation of disruptive technologies and analytical methods to serve research, clinical research, and clinical diagnostics across a range of fields from infectious disease and cancer to rare and chronic diseases.
Lennon has been with the Broad since 2005, and has contributed to the development of applications for every major genomics technology. He also built a CLIA/CAP licensed clinical laboratory at the Broad (now known as Broad Clinical Labs) to facilitate return of results to patients and to support clinical trials. More recently, Lennon has led efforts to achieve FDA approval for both large-scale genomics projects (NIH’s All of Us Research Program) and for Broad’s own clinical diagnostic for COVID-19 testing process that delivered more than 37M diagnostic test results to people in the New England region.
Niall Lennon is the senior director of the genomics platform at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is also the chief scientific officer and chair of the board of Broad Clinical Laboratories, a wholly owned subsidiary of the institute, and an associate director of the Gerstner Center for Cancer Diagnostics. He oversees the development, implementation, validation, and operation of disruptive technologies and analytical methods to serve research, clinical research, and clinical diagnostics across a range of fields from infectious disease and cancer to rare and chronic diseases.
Lennon has been with the Broad since 2005, and has contributed to the development of applications for every major genomics technology. He also built a CLIA/CAP licensed clinical laboratory at the Broad (now known as Broad Clinical Labs) to facilitate return of results to patients and to support clinical trials. More recently, Lennon has led efforts to achieve FDA approval for both large-scale genomics projects (NIH’s All of Us Research Program) and for Broad’s own clinical diagnostic for COVID-19 testing process that delivered more than 37M diagnostic test results to people in the New England region.
Fireside Chat:
Fireside Chat:
Morgan Maeder Head of Research
Aurora Therapeutics
Morgan Maeder is currently the Head of Research at Aurora Therapeutics. She earned her Ph.D. in Genetics from Harvard University in the lab of J. Keith Joung where her work spanned multiple platforms, from zinc fingers and TALEs to CRISPR-Cas9, and from nuclease-based gene editing to epigenetic-based gene regulation. As the first scientist at Editas Medicine, she led the preclinical development of EDIT-101, a CRISPR-Cas9-based gene editing approach to treat Leber Congenital Amaurosis type 10. Following Editas, she spent 1.5 years as a consultant to Third Rock Ventures, helping to launch Faze Medicines, a company pioneering therapeutics based on biomolecular condensates. Most recently, she was the second employee at Chroma Medicine, where she served as Head of Platform Technologies, working to develop programmable epigenetic editors to specifically modulate gene expression as a novel approach to genetic medicine.
Morgan Maeder is currently the Head of Research at Aurora Therapeutics. She earned her Ph.D. in Genetics from Harvard University in the lab of J. Keith Joung where her work spanned multiple platforms, from zinc fingers and TALEs to CRISPR-Cas9, and from nuclease-based gene editing to epigenetic-based gene regulation. As the first scientist at Editas Medicine, she led the preclinical development of EDIT-101, a CRISPR-Cas9-based gene editing approach to treat Leber Congenital Amaurosis type 10. Following Editas, she spent 1.5 years as a consultant to Third Rock Ventures, helping to launch Faze Medicines, a company pioneering therapeutics based on biomolecular condensates. Most recently, she was the second employee at Chroma Medicine, where she served as Head of Platform Technologies, working to develop programmable epigenetic editors to specifically modulate gene expression as a novel approach to genetic medicine.
Christalyn Rhodes, Ph.D.
CEO and Founder Harmonie Health
Christalyn Rhodes is a biotech influencer and strategist who operates at the intersection of science and business to transform how medicines are discovered, developed, and delivered. As Lilly’s Associate Vice President of External Partnerships for Genetic Medicines, she scouted pivotal breakthrough technologies and built the infrastructure to accelerate their development. When gaps exist, she steps in as an inventor and interdisciplinary scientist, creating nuanced solutions and new platforms. Previously an investor and biotech entrepreneur, she identified high-impact opportunities and founded companies focused on diseases with substantial economic burden—designing technologies and authoring four pivotal patents that reversed the trajectory of a failing company and delivered more than $50 million in savings. She is committed to catalyzing life-saving therapies through collaborative efforts across academia and industry.
Dr. Christalyn Rhodes is a biotech executive and founder operating at the intersection of genetic medicine, AI, and human performance. She began her industry career at Flagship Pioneering, where she helped incubate novel therapeutic platforms and later co-founded an RNA editing company focused on precision genetic interventions. She went on to serve as Associate Vice President of Genetic Medicine at Eli Lilly, leading external innovation and partnerships to accelerate next-generation RNA and gene-based therapies. Previously, Dr. Rhodes was Head of Academic Partnerships and Expert-in-Residence at the Harvard Innovation Labs, advising startups at the interface of science, healthcare, and technology and building pipelines between academic founders and industry. She is currently the Founder and CEO of Harmonie Health, a digital biotherapeutics startup using agentic AI, real-time wearable data, and adaptive music to directly modulate pain and stress responses. Across roles, Dr. Rhodes has built a reputation as a strategic connector of disciplines, translating complex biology into scalable platforms and partnering models that serve patients, clinicians, and innovators alike. She earned her PhD from Harvard University and is currently a Sloan Fellow at MIT Sloan School of Management.
When & Where:
When & Where
November 20, 2025 | 3:00 PM - 6:00 PM
LabCentral Lobby | 700 Main Street, Cambridge, MA
November 20, 2025 | 3:00 PM - 6:00 PM
LabCentral Lobby | 700 Main St., Cambridge, MA
November 20, 2025 | 3:00 PM - 6:00 PM
LabCentral Lobby | 700 Main St.